772:
183:
70:
25:
138:
have raised ~$ 4B since inception and have generally shared a similar investment strategy of financing projects and ideas in the life sciences and technology sectors. The firms distinguish themselves on the basis of their target geographies, stage of investment, and sectors. They have been independent entities since 1997.
1075:
2013 - Sofinnova
Ventures worked with General Partner Garheng Kong to spin out a new fund, called HealthQuest Capital. HQC's mandate is to provide growth capital to companies transforming healthcare, with a focus on companies other than drug development. HQC raised their second fund, at $ 225M, in
321:
Sofinnova
Partners most recently closed its Sofinnova Telethon Fund at €108 M and has invested in 3 Italian biotech startups in the last 6 months. This fund specializes in early‐stage investments in gene and cell therapies and is based out of Milan, Italy. It also completed fundraising for its ninth
1057:
2007 - SVP VII was raised, which was
Sofinnova Ventures' first fund that was overwhelmingly focused on Life Science (80%+), with emphasis on drug development. Their next fund, SVP VIII in 2011 was exclusively (100%) Life Science. At the same time, Sofinnova Partners in Paris moved from a balanced
624:
Sofinnova
Ventures has raised several venture capital funds (see Table). The earlier funds, SVP I through V, were predominantly information technology (IT), wherein the later funds were predominantly life science focused. SVP VIII and IX were exclusively life science only, with emphasis on Phase 2
137:
firms, Sofinnova
Partners and Sofinnova Ventures. The name Sofinnova is a contraction of the French, "Société de Financement de l’Innovation" or, Innovation Venture Capital Company. Both firms trace their roots back to Sofinnova SA, an investment institution founded in Paris in 1972. The two firms
1046:
2003 - Sofinnova
Ventures started its EIR/Executive Partner program in Life Sciences, with its first EIR Barry Selick. Following this, several other EIRs/Executive Partners joined Sofinnova Ventures from then until 2015, including: Jeff Stein, David Kabakoff, Bill Ringo (Strategic Advisor), Goro
325:
Some notable investments from the firm's flagship fund include Innate, Maximiles and NovusPharma from
Sofinnova Capital III (€121M). Sofinnova Partners' Capital IV fund, which raised €330M of capital, made it one of the largest venture firms in Europe at the time. In 2005, Sofinnova Partners was
326:
named “Fund of the Year” by
Private Equity International and “VC Techno House of the Year 2005” by the European Venture Capital Journal (EVCJ) which described Sofinnova's fundraising as the “Fundraising of the Year 2005”. This fund invested in a number of companies including
625:
and 3 drug development. SVP IV was
Sofinnova Ventures' initial fund after the reorganization of Sofinnova in 1997. Each of the funds from SVP V through SVP IX exceeded the target raise, and closed at the maximum amount as allowed by the Limited Partner agreements.
522:
Jim Healy, MD, PhD, Mike Powell, PhD, Alan
Colowick, MD, Lars Ekman, MD, David Kabakoff, PhD, Dan Welch, Heather Behanna, Phd, Sarah Bhagat, PhD, Nathalie Auber, Hooman Shalavi, Charlotte Shropshire, Alain Azan (Retired), Jean Deleage
1016:
1997 - The global Sofinnova organization restructured, formally creating two separate management companies, one for Sofinnova Ventures, and one for Sofinnova Partners. The reorganization was done on the basis of geography, creating
919:, was a board member of Sofinnova SA in its early years. Sofinnova SA quickly established a presence in the European market through the formation of Sofinnova Partners in Paris. Sofinnova SA owned this firm from 1972 until 1997.
979:
to take over management of Sofinnova Ventures, replacing Jean-Bernard Schmidt. Schmidt would be named Chairman of Sofinnova, retaining that position through 2007. Sofinnova Ventures completed fundraising for SVP I, which was a
922:
1974 - Sofinnova became the first European venture company to enter the US market launching its US affiliate, Sofinnova, Inc (Sofinnova Ventures). Sofinnova co-founder, Jean Deleage, who would later co-found US venture firm
892:
1071:
2010 - Sofinnova Partners started their Green Seed Fund and hired Joško Bobanović to manage this new initiative. In 2012, this seed fund initiative was announced in conjunction with the Sofinnova Capital VII
155:
Sofinnova Partners and Sofinnova Ventures have historically shared some of the same Limited Partners, and have co-invested together in various life sciences companies including Flamel, Cerep, Genset,
1050:
2006 - Sofinnova Ventures and Sofinnova Partners first sponsored the Sofinnova Biopharm Partnering Conference in Japan, headed up by Sofinnova's Goro Takeda. In 2014, the conference teamed up with
885:
1506:
617:
in the office of one of the Managing Partners (Mike Powell). Sofinnova Ventures closed their San Francisco office in 2011, and combined their Bay Area offices into a single office on
878:
471:
984:
originally intended to invest in European companies expanding in the US. Ultimately, Sofinnova Venture Partners would shift its focus toward investments in domestic US companies.
1080:
1061:
2008 - Sofinnova Ventures made its last IT investment (Enovix). The remaining IT team was active for several years after this to monitor and monetize the final IT investments.
1516:
145:
is based in Paris, London, and Milan and focuses primarily on European biotech, medtech, biopharma, and industrial biotech investments, with a similar allocation for the US.
1241:
1295:
1526:
1361:
1353:
761:
1013:. Prior to the 1997 reorganization, Sofinnova Ventures raised three venture funds totaling $ 57M, and Sofinnova Partners raised funds with €85M in commitments.
1039:
2000 - Sofinnova Ventures hires Jim Healy, MD, PhD and together he and Mike Powell, PhD rebuilt the Sofinnova Ventures LS brand, with focus on clinical stage
1485:
954:
and ultimately other US firms. Jean-Bernard Schmidt, who would later serve as Chairman of Sofinnova, was named the head of US operations of Sofinnova, Inc.
285:
Over the last few years, Sofinnova Partners has created a platform strategy to include multiple funds alongside its historic Capital Fund. This includes:
1149:
1511:
1208:
302:
Each of these funds is managed by dedicated specialist teams and are unique investment vehicles across the life sciences investment value chain.
1174:
305:
Sofinnova has financed over 500 companies around the world since its inception in 1972 of which more than 20% have successfully completed an
1051:
1288:
915:) and was notable at the time for creating the first "American style" venture capital firm in France. Peter Brooke, the founder of
117:
470:
151:
has offices in Menlo Park, CA, and San Diego, CA, and focuses largely on US biotech investments, with ~20% allocation for Europe.
1521:
1366:
1338:
779:
99:
80:
45:
1480:
946:, which eventually became Sofinnova Ventures. Deleage departed Sofinnova in 1979 to co-found another venture capital firm
927:, was appointed the head of the US operation. Sofinnova's US business gained attention for its role as an early backer of
1475:
1281:
1227:
1104:
1083:, at €106 million. The fund, dedicated to renewable chemistry, follows a series of 9 investments in the sector since 2009.
275:
with approximately €2 billion of capital. The firm invests primarily in early-stage companies and corporate spin-offs, in
951:
947:
924:
37:
1381:
1376:
1371:
1136:
859:
847:
827:
811:
795:
745:
583:
450:
163:
relationship and exchange information and due diligence. The firms do not have an obligation to disclose deals or to
587:
41:
1432:
1407:
310:
276:
95:
965:
306:
1437:
509:
1462:
1273:
969:
911:
1972 - Sofinnova was founded with the backing of several French financial institutions (most notably
164:
1422:
1010:
988:
981:
992:
867:
613:
The San Francisco office of Sofinnova Ventures was often remembered for having an original 18ft.
607:
771:
1076:
2016, and transitioned to further independence from the parent Sofinnova Ventures organization.
289:
The Sofinnova Telethon Fund, specializing in early‐stage investments in gene and cell therapies
1442:
1333:
1196:
1026:
1006:
591:
1343:
1040:
928:
912:
819:
803:
599:
991:
in France, with €38M of investor commitments. Sofinnova's investments in this fund include
1447:
1402:
1323:
1308:
491:
481:
231:
193:
134:
182:
1397:
1328:
1304:
1029:, each of the management companies was solely owned by its respective management teams.
835:
787:
618:
203:
91:
1000:
1990s: The Reorganization of Sofinnova into Sofinnova Partners and Sofinnova Ventures
167:, but historically have co-invested together in ~10% of their collective investments.
1500:
1452:
1427:
1417:
976:
943:
916:
839:
582:
Sofinnova Ventures has been an active venture investor, investing in some well-known
221:
1457:
1412:
939:
282:
The Sofinnova Partners' flagship fund, Sofinnova Capital IX, raised €333M in 2019.
160:
1202:
987:
1989 - Sofinnova Partners completed fundraising for Sofinnova Capital, its first
531:
1247:
1150:"SOFINNOVA PARTNERS RAISES €333 MILLION CAPITAL IX EARLY-STAGE HEALTHCARE FUND"
1009:
itself from the Paris exchange to raise capital privately through traditional
614:
942:
established the American subsidiary of Sofinnova, called Sofinnova, Inc., in
932:
330:. Sofinnova Partners has raised several venture capital funds (see Table).
1058:
IT/LS venture firm, to one that was predominantly focused on Life Science.
292:
The Sofinnova Crossover I, a fund investing in pre‐ and post‐IPO companies
595:
159:, Preglem, Movetis, Ascendis, Obseva, Auris and Nucana. The firms have a
156:
603:
950:
In 1981, working with Deleage, Sofinnova developed a partnership with
24:
1175:"Sofinnova Partners Announces Third Investment from its Italian Fund"
268:
253:
1203:
The New Venturers: Inside the High-stakes World of Venture Capital
539:
327:
272:
264:
239:
34:
may have been created or edited in return for undisclosed payments
1277:
295:
The Sofinnova MD Start III, a medical device acceleration fund
63:
18:
1047:
Takeda, Jay Shepard, George Horner, Lars Ekman and Dan Welch.
322:
private equity fund, Sofinnova Capital IX with €333M raised.
574:
is an independent venture capital firm based in Menlo Park.
563:
1261:
602:, Cotherix, Threshold Pharmaceuticals, Prestwick, Preglem,
1267:
1079:
2017 - Sofinnova Partners announced the first closing of
1054:, making this the largest biopartnering meeting in Japan.
1228:
Accent to Expand with Investment from Sofinnova Partners
87:
586:. Sofinnova Ventures has backed companies including:
98:, and by adding encyclopedic content written from a
40:. It may require cleanup to comply with Knowledge's
1390:
1352:
1316:
559:
549:
537:
527:
516:
505:
497:
487:
477:
249:
237:
227:
217:
209:
199:
189:
1197:Done Deals: Venture Capitalists Tell Their Stories
1135:Based on capital raised since inception. Source:
1103:
1507:Financial services companies established in 1972
263:is an independent venture capital firm based in
142:
1034:2000s: The Move to Life Science for Sofinnova
1362:History of private equity and venture capital
1289:
886:
148:
8:
463:
175:
1066:2010s: New Growth Initiatives at Sofinnova
1517:Venture capital firms of the United States
1296:
1282:
1274:
893:
879:
757:
462:
181:
174:
118:Learn how and when to remove this message
627:
332:
1209:Sofinnova SA Public Repurchase offering
1092:
858:
846:
826:
810:
794:
778:
760:
171:Sofinnova Partners (France, UK, Italy)
79:contains content that is written like
1148:Huiban, Stéphanie (17 October 2019).
1131:
1129:
1127:
959:1980s: The Early Growth of Sofinnova
7:
1527:French companies established in 1972
1098:
1096:
1052:Biotechnology Industry Organization
995:as well as Cerep, Egide and Flamel.
298:The Sofinnova Industrial Biotech I
14:
906:1970s: The Founding of Sofinnova
584:venture investments of the period
1512:Companies based in San Francisco
1110:Gale Biography Online Collection
770:
725:Sofinnova Venture Partners VIII
469:
68:
23:
1367:Early history of private equity
822:and the venture capital bubble)
714:Sofinnova Venture Partners VII
670:Sofinnova Venture Partners III
1081:Sofinnova Industrial Biotech I
964:1985 - Sofinnova completed an
736:Sofinnova Venture Partners IX
703:Sofinnova Venture Partners VI
681:Sofinnova Venture Partners IV
659:Sofinnova Venture Partners II
1:
952:Burr, Egan, Deleage & Co.
948:Burr, Egan, Deleage & Co.
925:Burr, Egan, Deleage & Co.
692:Sofinnova Venture Partners V
648:Sofinnova Venture Partners I
36:, a violation of Knowledge's
1173:Lee, Bommy (20 April 2020).
938:1976 - Sofinnova co-founder
309:and more than 20% have been
16:French venture capital firms
1382:Private equity in the 2000s
1377:Private equity in the 1990s
1372:Private equity in the 1980s
1268:Sofinnova Partners (France)
1137:Private Equity Intelligence
975:1987 - Alain Azan moved to
746:Private Equity Intelligence
451:Private Equity Intelligence
1543:
588:Millennium Pharmaceuticals
133:is the name shared by two
1471:
1433:High-net-worth individual
1408:Corporate venture capital
1244:. Business Week Profile.
1179:www.sofinnovapartners.com
1154:www.sofinnovapartners.com
762:History of private equity
468:
180:
1025:in Europe. Following a
459:Sofinnova Ventures (USA)
277:industrial biotechnology
1262:Sofinnova Ventures (US)
1250:, University of Toronto
1199:, 2000. p. 249-250
966:initial public offering
430:Sofinnova Capital VIII
307:initial public offering
1522:Life sciences industry
1438:Institutional investor
1105:"Jean-Bernard Schmidt"
968:with a listing on the
610:, Salveo, and Labrys.
510:Menlo Park, California
419:Sofinnova Capital VII
375:Sofinnova Capital III
279:and in life sciences.
1481:Venture capital firms
1463:Sovereign wealth fund
441:Sofinnova Capital IX
408:Sofinnova Capital VI
386:Sofinnova Capital IV
364:Sofinnova Capital II
313:by strategic buyers.
100:neutral point of view
46:neutral point of view
1476:Private equity firms
1011:private equity funds
970:Paris Stock Exchange
397:Sofinnova Capital V
353:Sofinnova Capital I
1486:Portfolio companies
1317:Investment strategy
1205:, 1985. p. 117
989:private equity fund
982:private equity fund
935:in the early 1980s.
786:(origins of modern
764:and venture capital
551:Number of employees
465:
177:
92:promotional content
1242:Sofinnova Ventures
1235:Sofinnova Ventures
1221:Sofinnova Partners
1023:Sofinnova Partners
1019:Sofinnova Ventures
993:Genset Corporation
868:COVID-19 recession
608:Amarin Corporation
572:Sofinnova Ventures
464:Sofinnova Ventures
261:Sofinnova Partners
176:Sofinnova Partners
149:Sofinnova Ventures
143:Sofinnova Partners
94:and inappropriate
1494:
1493:
1443:Insurance company
1270:- company website
1264:- company website
1027:management buyout
1005:1993 - Sofinnova
903:
902:
750:
740:
739:
592:Kosan Biosciences
569:
568:
564:www.sofinnova.com
455:
445:
444:
258:
257:
128:
127:
120:
62:
61:
1534:
1344:Leveraged buyout
1311:investment firms
1298:
1291:
1284:
1275:
1189:
1188:
1186:
1185:
1170:
1164:
1163:
1161:
1160:
1145:
1139:
1133:
1122:
1121:
1119:
1117:
1107:
1100:
1041:drug development
929:Tandem Computers
895:
888:
881:
820:leveraged buyout
804:leveraged buyout
774:
758:
742:
628:
600:Seattle Genetics
542:
473:
466:
447:
333:
242:
185:
178:
123:
116:
112:
109:
103:
81:an advertisement
72:
71:
64:
57:
54:
42:content policies
27:
19:
1542:
1541:
1537:
1536:
1535:
1533:
1532:
1531:
1497:
1496:
1495:
1490:
1467:
1448:Investment bank
1403:Commercial bank
1386:
1348:
1312:
1309:venture capital
1302:
1258:
1253:
1237:
1232:
1223:
1218:
1192:
1183:
1181:
1172:
1171:
1167:
1158:
1156:
1147:
1146:
1142:
1134:
1125:
1115:
1113:
1102:
1101:
1094:
1090:
1068:
1036:
1002:
961:
913:Crédit National
908:
899:
763:
756:
621:in Menlo Park.
606:, Intellikine,
580:
552:
538:
519:
512:, United States
492:Venture Capital
461:
319:
245:over €2 billion
238:
232:Venture capital
173:
135:venture capital
124:
113:
107:
104:
85:
73:
69:
58:
52:
49:
44:, particularly
28:
17:
12:
11:
5:
1540:
1538:
1530:
1529:
1524:
1519:
1514:
1509:
1499:
1498:
1492:
1491:
1489:
1488:
1483:
1478:
1472:
1469:
1468:
1466:
1465:
1460:
1455:
1450:
1445:
1440:
1435:
1430:
1425:
1420:
1415:
1410:
1405:
1400:
1398:Angel investor
1394:
1392:
1388:
1387:
1385:
1384:
1379:
1374:
1369:
1364:
1358:
1356:
1350:
1349:
1347:
1346:
1341:
1336:
1331:
1326:
1320:
1318:
1314:
1313:
1305:Private equity
1303:
1301:
1300:
1293:
1286:
1278:
1272:
1271:
1265:
1257:
1256:External links
1254:
1252:
1251:
1245:
1238:
1236:
1233:
1231:
1230:
1224:
1222:
1219:
1217:
1216:
1206:
1200:
1193:
1191:
1190:
1165:
1140:
1123:
1091:
1089:
1086:
1085:
1084:
1077:
1073:
1067:
1064:
1063:
1062:
1059:
1055:
1048:
1044:
1035:
1032:
1031:
1030:
1021:in the US and
1014:
1001:
998:
997:
996:
985:
973:
960:
957:
956:
955:
936:
920:
907:
904:
901:
900:
898:
897:
890:
883:
875:
872:
871:
863:
862:
856:
855:
851:
850:
844:
843:
836:dot-com bubble
831:
830:
824:
823:
815:
814:
808:
807:
799:
798:
792:
791:
788:private equity
783:
782:
776:
775:
767:
766:
755:
752:
749:and Sofinnova.
738:
737:
734:
731:
727:
726:
723:
720:
716:
715:
712:
709:
705:
704:
701:
698:
694:
693:
690:
687:
683:
682:
679:
676:
672:
671:
668:
665:
661:
660:
657:
654:
650:
649:
646:
643:
639:
638:
635:
632:
619:Sand Hill Road
579:
576:
567:
566:
561:
557:
556:
553:
550:
547:
546:
543:
535:
534:
529:
525:
524:
520:
517:
514:
513:
507:
503:
502:
499:
495:
494:
489:
485:
484:
479:
475:
474:
460:
457:
443:
442:
439:
436:
432:
431:
428:
425:
421:
420:
417:
414:
410:
409:
406:
403:
399:
398:
395:
392:
388:
387:
384:
381:
377:
376:
373:
370:
366:
365:
362:
359:
355:
354:
351:
348:
344:
343:
340:
337:
318:
315:
300:
299:
296:
293:
290:
256:
255:
251:
247:
246:
243:
235:
234:
229:
225:
224:
219:
215:
214:
211:
207:
206:
204:Private equity
201:
197:
196:
191:
187:
186:
172:
169:
153:
152:
146:
126:
125:
96:external links
76:
74:
67:
60:
59:
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
1539:
1528:
1525:
1523:
1520:
1518:
1515:
1513:
1510:
1508:
1505:
1504:
1502:
1487:
1484:
1482:
1479:
1477:
1474:
1473:
1470:
1464:
1461:
1459:
1456:
1454:
1453:Merchant bank
1451:
1449:
1446:
1444:
1441:
1439:
1436:
1434:
1431:
1429:
1428:Fund of funds
1426:
1424:
1421:
1419:
1418:Family office
1416:
1414:
1411:
1409:
1406:
1404:
1401:
1399:
1396:
1395:
1393:
1389:
1383:
1380:
1378:
1375:
1373:
1370:
1368:
1365:
1363:
1360:
1359:
1357:
1355:
1351:
1345:
1342:
1340:
1337:
1335:
1332:
1330:
1327:
1325:
1322:
1321:
1319:
1315:
1310:
1306:
1299:
1294:
1292:
1287:
1285:
1280:
1279:
1276:
1269:
1266:
1263:
1260:
1259:
1255:
1249:
1248:DISTILLATIONS
1246:
1243:
1240:
1239:
1234:
1229:
1226:
1225:
1220:
1214:
1210:
1207:
1204:
1201:
1198:
1195:
1194:
1180:
1176:
1169:
1166:
1155:
1151:
1144:
1141:
1138:
1132:
1130:
1128:
1124:
1111:
1106:
1099:
1097:
1093:
1087:
1082:
1078:
1074:
1072:announcement.
1070:
1069:
1065:
1060:
1056:
1053:
1049:
1045:
1042:
1038:
1037:
1033:
1028:
1024:
1020:
1015:
1012:
1008:
1004:
1003:
999:
994:
990:
986:
983:
978:
977:San Francisco
974:
971:
967:
963:
962:
958:
953:
949:
945:
944:San Francisco
941:
937:
934:
930:
926:
921:
918:
917:TA Associates
914:
910:
909:
905:
896:
891:
889:
884:
882:
877:
876:
874:
873:
869:
865:
864:
861:
857:
853:
852:
849:
845:
841:
840:credit crunch
837:
833:
832:
829:
825:
821:
817:
816:
813:
809:
805:
801:
800:
797:
793:
789:
785:
784:
781:
780:Early history
777:
773:
769:
768:
765:
759:
753:
751:
748:
747:
735:
732:
729:
728:
724:
721:
718:
717:
713:
710:
707:
706:
702:
699:
696:
695:
691:
688:
685:
684:
680:
677:
674:
673:
669:
666:
663:
662:
658:
655:
652:
651:
647:
644:
641:
640:
636:
633:
630:
629:
626:
622:
620:
616:
611:
609:
605:
601:
598:, Intermune,
597:
593:
589:
585:
577:
575:
573:
565:
562:
558:
554:
548:
544:
541:
536:
533:
530:
526:
521:
515:
511:
508:
504:
500:
496:
493:
490:
486:
483:
480:
476:
472:
467:
458:
456:
454:
453:and Sofinnova
452:
440:
437:
434:
433:
429:
426:
423:
422:
418:
415:
412:
411:
407:
404:
401:
400:
396:
393:
390:
389:
385:
382:
379:
378:
374:
371:
368:
367:
363:
360:
357:
356:
352:
349:
346:
345:
341:
338:
335:
334:
331:
329:
323:
316:
314:
312:
308:
303:
297:
294:
291:
288:
287:
286:
283:
280:
278:
274:
270:
266:
262:
254:
252:
248:
244:
241:
236:
233:
230:
226:
223:
222:Paris, France
220:
216:
212:
208:
205:
202:
198:
195:
192:
188:
184:
179:
170:
168:
166:
162:
158:
150:
147:
144:
141:
140:
139:
136:
132:
122:
119:
111:
101:
97:
93:
89:
83:
82:
77:This article
75:
66:
65:
56:
47:
43:
39:
35:
32:This article
30:
26:
21:
20:
1458:Pension fund
1413:Crowdfunding
1212:
1182:. Retrieved
1178:
1168:
1157:. Retrieved
1153:
1143:
1114:. Retrieved
1112:. Gale. 2003
1109:
1022:
1018:
940:Jean Deleage
743:
741:
623:
612:
581:
571:
570:
540:Total assets
506:Headquarters
478:Company type
448:
446:
324:
320:
304:
301:
284:
281:
260:
259:
240:Total assets
218:Headquarters
190:Company type
154:
130:
129:
114:
108:October 2020
105:
90:by removing
86:Please help
78:
53:October 2021
50:
38:terms of use
33:
1339:Secondaries
854:(expansion)
578:Investments
532:Investments
317:Investments
1501:Categories
1184:2020-05-19
1159:2020-05-19
1088:References
1043:companies.
615:Mosasaurus
523:(Deceased)
518:Key people
88:improve it
1423:Endowment
1391:Investors
1334:Mezzanine
933:Genentech
860:The 2020s
848:The 2010s
828:The 2000s
812:The 1990s
796:The 1980s
165:co-invest
161:collegial
131:Sofinnova
1116:7 August
1007:delisted
744:Source:
596:Actelion
528:Products
488:Industry
449:Source:
311:acquired
228:Products
200:Industry
157:Actelion
1354:History
1324:Venture
838:to the
754:History
604:Movetis
560:Website
498:Founded
482:Private
250:Website
210:Founded
194:Private
1329:Growth
1213:French
733:$ 510M
722:$ 440M
711:$ 375M
700:$ 250M
689:$ 210M
634:Amount
545:$ 1.9B
339:Amount
271:, and
269:London
806:boom)
678:$ 72M
667:$ 31M
656:$ 20M
637:Fund
438:€333M
427:€300M
416:€240M
405:€260M
394:€385M
383:€330M
372:€121M
342:Fund
328:Taptu
273:Milan
265:Paris
1307:and
1118:2020
931:and
730:2014
719:2011
708:2007
697:2003
686:2000
675:1998
664:1994
653:1991
645:$ 6M
642:1984
631:Year
501:1974
435:2019
424:2015
413:2012
402:2010
391:2005
380:2001
369:1998
361:€47M
358:1994
350:€38M
347:1989
336:Year
213:1972
555:~20
48:.
1503::
1177:.
1152:.
1126:^
1108:.
1095:^
594:,
590:,
267:,
1297:e
1290:t
1283:v
1215:)
1211:(
1187:.
1162:.
1120:.
972:.
894:e
887:t
880:v
870:)
866:(
842:)
834:(
818:(
802:(
790:)
121:)
115:(
110:)
106:(
102:.
84:.
55:)
51:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
